Application of compound Pien Tze Huang buccal tablets in preparation of medicine for preventing and / or treating throat reflux diseases

Through the combined use of compound Pills and proton pump inhibitors, the problem of long cycles and recurrence in existing treatment methods has been solved, significantly improved the symptoms of throat reflux disease, and provided a new treatment idea with a wide range of Application prospects.

CN118903309APending Publication Date: 2024-11-08ZHANGZHOU PIEN TZE HUANG PHARM
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410953389.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing treatments for laryngeal reflux diseases such as proton pump inhibitors and H2 receptor inhibitors have problems with long cycles and prone to recurrence, and lack effective novel treatment methods.

Method used

采用复方片仔癀含片与质子泵抑制剂联合使用,通过改善咽喉反流症状指数评分,降低反流症状指数,并结合蟛蜞菊、肿节风、玄参、麦冬、甘草、薄荷脑及片仔癀等成分制备的药物。

Benefits of technology

It significantly improves the symptoms of LPRD patients, has faster and more effective therapeutic effects, and provides a new clinical treatment method with broad application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903309A_ABST
    Figure CN118903309A_ABST
Patent Text Reader

Abstract

The invention provides a novel application of a compound Pien Tze Huang lozenge in treating throat reflux diseases, and belongs to the field of biological medicines. It is found for the first time that the compound Pien Tze Huang lozenge can effectively treat the throat reflux disease, and the compound Pien Tze Huang lozenge has a wide application prospect in preparation of the medicine for preventing and / or treating the throat reflux disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and in particular relates to use of compound Pien Tze Huang lozenges in preparing medicines for preventing and / or treating laryngopharyngeal reflux disease. Background Art

[0002] Laryngopharyngeal reflux disease (LPRD) is a general term for chronic inflammation and signs such as pharyngeal edema and ulcers caused by the reflux of gastric contents (such as pepsin, deoxycholic acid, etc.) to the area above the upper esophageal sphincter. The main symptoms include hoarseness, sore throat and chronic cough. Severe LPRD may cause malignant tumors in the throat, and LPRD is related to the occurrence of diseases such as asthma, allergic rhinitis and chronic otitis media with effusion. Western medicine believes that LPRD is related to factors such as the destruction of anti-reflux function, neuroinflammation, and lifestyle and diet. At present, the main clinical treatment methods are oral proton pump inhibitors (PPI), H2 receptor inhibitors H2RA, prokinetic drugs and surgery to relieve patients' LPRD symptoms. However, taking the above drugs has the disadvantages of long cycles, easy recurrence, and difficult to cure patients. Therefore, new LPRD treatment methods need to be developed.

[0003] Compound Pien Tze Huang Lozenges are a Chinese patent medicine composed of Wedelia officinalis, Sarcandra chinensis, Scrophularia ningpoensis, Radix Ophiopogonis, Licorice, Menthol and Pien Tze Huang, a national secret formula drug, which has the effect of clearing away heat and detoxifying and has been used clinically for a long time. However, there are no reports on the use of Compound Pien Tze Huang Lozenges for the treatment of laryngopharyngeal reflux disease. Summary of the invention

[0004] The purpose of the present invention is to provide a new use of the compound Pien Tze Huang lozenge in treating laryngopharyngeal reflux disease.

[0005] The invention provides use of compound Pien Tze Huang lozenges in preparing medicine for preventing and / or treating laryngopharyngeal reflux disease.

[0006] Furthermore, the drug is a drug for improving laryngopharyngeal reflux symptoms.

[0007] Furthermore, the drug is a drug that reduces the reflux symptom index score.

[0008] Furthermore, the compound Pien Tze Huang lozenge is a preparation prepared with Wedelia chrysanthemum, Sarcophagnum recutita, Scrophularia ningpoensis, Ophiopogon japonicus, Licorice, menthol and Pien Tze Huang as active ingredients, and with mannitol, dextrin, pregelatinized starch, corn protein, magnesium stearate, aspartame and film coating premix as auxiliary materials.

[0009] Furthermore, the compound Pien Tze Huang lozenge is a commercially available product purchased from Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

[0010] The present invention also provides the use of the compound Pien Tze Huang lozenges in combination with a proton pump inhibitor in the preparation of a medicine for preventing and / or treating laryngopharyngeal reflux disease.

[0011] Furthermore, the proton pump inhibitor is an oral proton pump inhibitor.

[0012] Furthermore, the oral proton pump inhibitor is oral rabeprazole sodium.

[0013] Furthermore, the oral rabeprazole sodium is rabeprazole sodium enteric-coated capsules.

[0014] Furthermore, the mass ratio of the compound Pien Tze Huang lozenge to the proton pump inhibitor is (200-300):1.

[0015] Furthermore, the mass ratio of the compound Pien Tze Huang lozenge to the proton pump inhibitor is 250:1.

[0016] Furthermore, the compound Pien Tze Huang lozenge and the proton pump inhibitor are administered simultaneously or separately.

[0017] The present invention firstly finds that compared with the use of PPI alone, the combined use of compound Pien Tze Huang lozenges and PPI drugs can more significantly improve the symptoms of LPRD patients, and there is a statistical difference. The present invention firstly finds that compound Pien Tze Huang lozenges can effectively treat laryngopharyngeal reflux disease, and has broad application prospects in the preparation of drugs for preventing and / or treating laryngopharyngeal reflux disease.

[0018] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0019] The above contents of the present invention are further described in detail below through specific implementation methods in the form of examples. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 A flowchart of the treatment plan.

[0021] Figure 2 This is the changing trend of RSI scores in the control group and the combined treatment group. DETAILED DESCRIPTION

[0022] The raw materials and equipment used in the present invention are all known products, which are obtained by purchasing commercially available products.

[0023] Compound Pien Tze Huang lozenges were purchased from Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

[0024] Example 1: Effect of Compound Pien Tze Huang Lozenges in Treating Laryngopharyngeal Reflux Disease

[0025] 1. Research subjects

[0026] This study was designed as a prospective randomized controlled trial. The subjects were patients who presented with throat discomfort, had a reflux symptom index score (RSI) >13 points, and had a positive salivary pepsin test. The specific inclusion criteria included: (1) age ≥18 years; (2) had one or more symptoms in the laryngopharyngeal reflux symptom scale and an overall RSI >13 points; (3) had a salivary pepsin test (Peptest) index greater than 16 ng / ml; (4) had no contraindications to the use of PPI drugs or Pien Tze Huang, such as gastrointestinal malignancies, severe liver function abnormalities, and pregnancy or lactation; and (5) agreed to be included in the study and could cooperate with the treatment and follow-up.

[0027] The scoring method of the Reflux Symptom Index (RSI) is shown in Table 1 below (referenced by the Laryngology Group of the Editorial Committee of the Chinese Journal of Otolaryngology-Head and Neck Surgery, the Laryngology Group of the Otolaryngology-Head and Neck Surgery Branch of the Chinese Medical Association, and the Expert Consensus on the Diagnosis and Treatment of Laryngopharyngeal Reflux Disease (2015)).

[0028] Table 1 Reflux Symptom Index Scoring Scale

[0029]

[0030] The exclusion criteria for this study are as follows: (1) symptoms before treatment and the presence of allergic rhinitis, sinusitis, tonsillitis or other upper respiratory tract diseases assessed by electronic nasopharyngolaryngoscope; (2) pregnant or lactating women; and (3) those who do not agree to be included in the study or cannot guarantee cooperation with the full course of treatment and follow-up.

[0031] In addition, patients withdrew from the study and their data were no longer included in the final analysis due to the following circumstances during the follow-up period, including: (1) those who were lost to follow-up or unable to cooperate with the follow-up; (2) those who could not continue drug treatment due to various discomforts; (3) those who failed to take medication regularly; and (4) those who developed acute upper respiratory tract infection or allergies during treatment.

[0032] 2. Treatment plan

[0033] All patients were randomly assigned to the combined treatment group and the control group according to the random number table method. Both groups were given PPI drugs, specifically rabeprazole sodium enteric-coated capsules (dosage form: 20 mg / tablet, Shandong Jichuan Pharmaceutical Co., Ltd.), 20 mg orally, once a day. The combined treatment group was given compound Pien Tze Huang lozenges (dosage form: 0.5 g / tablet, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.), 1 g orally, 5 times a day.

[0034] 3. Treatment results

[0035] A total of 51 patients were included in this study, including 26 in the control group and 25 in the combined treatment group. During the follow-up, 2 patients gave up treatment, including 1 patient in the control group who gave up treatment due to dizziness and discomfort after 3 days of medication, and 1 patient in the combined treatment group who gave up treatment due to nausea and other discomfort after 1 week of medication. In addition, 1 patient in the control group and 2 patients in the combined treatment group were lost to follow-up. Therefore, the number of patients in the two groups finally included in the analysis was 24 (control group) and 22 (combined treatment group) (see Figure 1 There was no significant difference in the baseline data between the two groups (see Table 2).

[0036] Table 2. Comparison of baseline data between the control group and the combined treatment group

[0037]

[0038] Compared with the RSI before treatment, the RSI values ​​of the two groups of patients decreased significantly one week after treatment (P<0.001). Figure 2 As shown in the figure, at the end of the 1st to 3rd week of follow-up, the RSI scores in the combined treatment group were lower than those in the control group, and there was a significant difference between the two groups (P<0.05).

[0039] Table 3. Comparison of RSI between the control group and the combined treatment group at different time points

[0040]

[0041] 4. Conclusion

[0042] The above studies show that in the treatment of LPRD patients, the combination of PPI drugs with compound Pien Tze Huang lozenges can help control symptoms more quickly and better. Therefore, compound Pien Tze Huang lozenges are expected to become a new and effective means of clinical treatment of LPRD.

[0043] The present invention discloses the evaluation of the therapeutic effect of two groups of LPRD patients after taking PPI alone and taking compound Pien Tze Huang lozenges on the basis of PPI alone, and compares the reflux symptom index score (RSI) of the included LPRD patients taking PPI alone and taking the combined drugs. It is clear that compared with taking PPI alone, the combined use of compound Pien Tze Huang lozenges and PPI drugs can more significantly improve the symptoms of LPRD patients, and there is a statistical difference in the first to third weeks. This increases the clinical indications of compound Pien Tze Huang lozenges and provides a new clinical medication idea for the treatment of LPRD.

[0044] In summary, the present invention discovers for the first time that the compound Pien Tze Huang lozenges can effectively treat laryngopharyngeal reflux disease, and has broad application prospects in the preparation of drugs for preventing and / or treating laryngopharyngeal reflux disease.

Claims

1. Use of the compound Pien Tze Huang lozenge in preparing a medicine for preventing and / or treating laryngopharyngeal reflux disease.

2. The use according to claim 1, characterized in that The medicine is a medicine for improving laryngopharyngeal reflux symptoms.

3. The use according to claim 1, characterized in that The drug is a drug that reduces Reflux Symptom Index scores.

4. The use according to any one of claims 1 to 3, characterized in that: The compound Pien Tze Huang lozenge is a preparation prepared with Wedelia officinalis, Sarcandra chinensis, Scrophularia ningpoensis, Ophiopogon japonicus, Licorice, menthol and Pien Tze Huang as active ingredients, and with mannitol, dextrin, pregelatinized starch, corn protein, magnesium stearate, aspartame and film coating premix as auxiliary materials.

5. Use of the compound Pien Tze Huang lozenges in combination with a proton pump inhibitor in the preparation of a medicament for preventing and / or treating laryngopharyngeal reflux disease.

6. The use according to claim 5, characterized in that The proton pump inhibitor is an oral proton pump inhibitor.

7. The use according to claim 6, characterized in that The oral proton pump inhibitor is oral rabeprazole sodium.

8. The use according to any one of claims 5 to 7, characterized in that: The mass ratio of the compound Pien Tze Huang lozenge to the proton pump inhibitor is (200-300):

1.

9. The use according to claim 8, characterized in that The mass ratio of the compound Pien Tze Huang lozenge to the proton pump inhibitor is 250:

1.

10. The use according to claim 5, characterized in that The compound Pien Tze Huang lozenge and the proton pump inhibitor are administered simultaneously or separately.

Citation Information

Patent Citations

  • Honeysuckle, smoked plum and Chinese olive lozenge as well as preparation method and application thereof

    CN104906347A

  • Traditional Chinese medicine composition for treating reflux pharyngolaryngitis and application thereof

    CN114177269A

  • Chinese medicine composition for treating acute and chronic largngopharyngitis and ts preparing method

    CN1899523A

  • Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease

    US20060046998A1